《大行》美銀升中生製藥(01177.HK)目標至5.9元 重申買入
美銀證券發表報告指,中國生物製藥(01177.HK)日前公布將有一項授權交易準備落實,而且公司預期創新藥的銷售佔比將於今年提高至逾50%,至2027年將達60%,而有關增長勢頭是由公司的「內部研發+對外授權」雙引擎策略所推動。另外,公司最近獲國家藥監局批准其TQC3721對治療慢性阻塞性肺病(COPD)的第三期臨床試驗。
該行將TQC3721的收入預測納入考量範圍,並將中生製藥2027年總收入預測上調1%;目標價由5.1元升至5.9元,重申「買入」評級,因公司的產品管線進展順利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.